Vectura and Mundipharma have signed an agreement for the development and commercialization of the VR2076 ICS/LABA/LAMA MDI, Vectura has announced. Skyepharma, which was acquired by Vectura earlier this year, had previously announced a development and commercialization deal for the MDI, then known as SKP-2076, in December 2015.
Mundipharma and a “US associated independent company” have successfully completed feasibility work and are now exercising an option to develop the product for the treatment of asthma, triggering a €1.5 million payment to Vectura, the company said. Potential milestone payments for the project total €46.5 million.
EU regulatory submissions for VR2076 are expected in late 2022 or early 2023.
Vectura CEO James Ward-Lilley said, “This agreement extends our relationship with Mundipharma by building on the existing flutiform collaboration and, along with the Novartis QVM149 DPI program, increases the Group’s exposure to the important emerging triple combination class. Fixed combination triple therapy treatment is expected to develop strongly and is likely to take significant share from both existing use of multiple “free combination” treatments as well as from the large volume of ICS/LABA combination treatment currently used. The recent changes to the GOLD guidelines in November highlight the importance of a triple therapy in asthma given the likelihood of reduced future usage of ICS in COPD patients.”
Read the Vectura press release.
